Search alternatives:
improvement decrease » improvements increased (Expand Search), improvement success (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search), fold increases (Expand Search)
improvement decrease » improvements increased (Expand Search), improvement success (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search), fold increases (Expand Search)
-
1
-
2
Summary of post-treatment disease course measures from MDMA-AT publications.
Published 2025Subjects: -
3
-
4
Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.
Published 2025Subjects: -
5
-
6
-
7
-
8
Summary of post-treatment disease course measures from off-label medications clinical trials.
Published 2025Subjects: -
9
Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.
Published 2025Subjects: -
10
Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.
Published 2025Subjects: -
11
Summary of post-treatment disease course measures from clinical trials with psychotherapies.
Published 2025Subjects: -
12
-
13
-
14
Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.
Published 2025Subjects: -
15
-
16
-
17
-
18
Phosphorylation as an Effective Tool to Improve Stability and Reduce Toxicity of Antimicrobial Peptides
Published 2024“…Among them, W<sub>3</sub>BipY<sub>8</sub>-P stood out as the most promising peptide, exhibiting similar antibacterial activity as its unphosphorylated analog W<sub>3</sub>BipY<sub>8</sub> but with significantly reduced hemolytic activity (19-fold decrease), cytotoxicity (3.3-fold decrease), and an extended serum half-life 6.3 times longer than W<sub>3</sub>BipY<sub>8</sub>. …”
-
19
-
20